These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8095924)

  • 21. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
    Netski D; Kozel TR
    Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown properties.
    Ramos CL; Fonseca FL; Rodrigues J; Guimarães AJ; Cinelli LP; Miranda K; Nimrichter L; Casadevall A; Travassos LR; Rodrigues ML
    Eukaryot Cell; 2012 Sep; 11(9):1086-94. PubMed ID: 22562469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
    Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
    Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan.
    Yauch LE; Lam JS; Levitz SM
    PLoS Pathog; 2006 Nov; 2(11):e120. PubMed ID: 17096589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
    Mukherjee J; Kozel TR; Casadevall A
    J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.
    Deshaw M; Pirofski LA
    Clin Exp Immunol; 1995 Mar; 99(3):425-32. PubMed ID: 7882565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semisynthetic Glycoconjugate Vaccine Candidates against
    Crawford CJ; Liporagi-Lopes L; Coelho C; Santos Junior SR; Moraes Nicola A; Wear MP; Vij R; Oscarson S; Casadevall A
    ACS Infect Dis; 2024 Jun; 10(6):2089-2100. PubMed ID: 38819951
    [No Abstract]   [Full Text] [Related]  

  • 28. Cryptococcal capsular polysaccharide-induced modulation of murine immune responses.
    Breen JF; Lee IC; Vogel FR; Friedman H
    Infect Immun; 1982 Apr; 36(1):47-51. PubMed ID: 6210638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM), associated with peritoneal antigen-presenting cells (APC): requirements for GXM, APC activation, and interleukin-12.
    Blackstock R; McElwee N; Neller E; Shaddix-White J
    Infect Immun; 2000 Sep; 68(9):5146-53. PubMed ID: 10948138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay.
    Belay T; Cherniak R
    Infect Immun; 1995 May; 63(5):1810-9. PubMed ID: 7537249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen.
    Percival A; Thorkildson P; Kozel TR
    Clin Vaccine Immunol; 2011 Aug; 18(8):1292-6. PubMed ID: 21697342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.
    Nakouzi A; Zhang T; Oscarson S; Casadevall A
    Vaccine; 2009 Jun; 27(27):3513-8. PubMed ID: 19464529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
    Mukherjee S; Lee S; Mukherjee J; Scharff MD; Casadevall A
    Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.
    Grinsell M; Weinhold LC; Cutler JE; Han Y; Kozel TR
    J Infect Dis; 2001 Aug; 184(4):479-87. PubMed ID: 11471106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.
    Maitta RW; Datta K; Lees A; Belouski SS; Pirofski LA
    Infect Immun; 2004 Jan; 72(1):196-208. PubMed ID: 14688097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.
    Monari C; Retini C; Casadevall A; Netski D; Bistoni F; Kozel TR; Vecchiarelli A
    Eur J Immunol; 2003 Apr; 33(4):1041-51. PubMed ID: 12672070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
    Duro RM; Netski D; Thorkildson P; Kozel TR
    Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide.
    Valadon P; Nussbaum G; Oh J; Scharff MD
    J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy.
    da Silva TA; Hauser PJ; Bandey I; Laskowski T; Wang Q; Najjar AM; Kumaresan PR
    Cytotherapy; 2021 Feb; 23(2):119-130. PubMed ID: 33303326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans.
    McFadden DC; Casadevall A
    J Immunol; 2004 Mar; 172(6):3670-7. PubMed ID: 15004170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.